Marcos Chertman, MD
Endocrinology, Diabetes & Metabolism · Miami, FLNPI 1003865262
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.3% of the total across 178 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 16.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,264, 4.6 times the $277 reported in 2019. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in FL, where the typical reported total is $3,445.
Across 178 payments — averaging $22.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$676
- Lilly USA, LLC$553
- Mannkind Corporation$351
- Amgen$336
- Tandem Diabetes Care, Inc.$333
- Xeris Pharmaceuticals, Inc.$273
- plus $2K from 23 others
What the payments were for
- Food & beverage$3,93797%
- Education$120%
- Gifts$952%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 34 | $676 |
| Lilly USA, LLC | 28 | $553 |
| Mannkind Corporation | 14 | $351 |
| Amgen(2 entities) | 18 | $336 |
| Tandem Diabetes Care, Inc. | 11 | $333 |
| Xeris Pharmaceuticals, Inc. | 13 | $273 |
| Sanofi-aventis U.S. LLC | 9 | $207 |
| Corcept Therapeutics | 8 | $186 |
| Insulet Corporation | 6 | $161 |
| Abbott | 3 | $145 |
| Recordati_rare_diseases_inc. | 5 | $127 |
| Shire North American Group Inc | 1 | $119 |
| Radius Health, Inc. | 6 | $107 |
| AbbVie | 3 | $55 |
| IBSA Pharma Inc. | 2 | $50 |
| Sequel Med Tech, LLC | 2 | $46 |
| Dexcom, Inc. | 2 | $39 |
| Ascend Therapeutics US, LLC | 2 | $36 |
| Madrigal Pharmaceuticals | 1 | $29 |
| Rhythm Pharmaceuticals, Inc. | 1 | $29 |
| Kyowa Kirin, Inc. | 1 | $27 |
| Amarin Pharma, Inc. | 1 | $24 |
| Neurocrine Biosciences, Inc. | 1 | $24 |
| Ascendis Pharma Endocrinology Inc | 1 | $22 |
| AstraZeneca | 1 | $21 |
| Halozyme Inc | 1 | $21 |
| Cequr Corporation | 1 | $17 |
| Merck | 1 | $15 |
| Alvogen Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Epic$103
How this compares
$4,045 in reported general payments places this provider in the 50th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
See all endocrinology, diabetes & metabolism providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 57 | $89,803 |
| MounjaroTirzepatide | 57 | $82,977 |
| Tresiba Flextouch U-200Insulin Degludec | 28 | $25,271 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 18 | $18,846 |
| JardianceEmpagliflozin | 14 | $16,359 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $12,286 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 16 | $10,716 |
| Tresiba Flextouch U-100Insulin Degludec | 21 | $7,810 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 11 | $7,426 |
| SynthroidLevothyroxine Sodium | 52 | $6,064 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 30 | $5,037 |
| Novolog FlexpenInsulin Aspart | 20 | $3,836 |
| Testosterone | 19 | $2,943 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $2,242 |
| Humalog Mix 75-25 KwikpenInsulin Lispro Protamin/Lispro | 14 | $2,238 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $676 | $89,80357 claims |
| Lilly USA, LLCMounjaro | $553 | $82,97757 claims |
| MerckJanumet Xr | $15 | $18,84618 claims |
| AbbVieSynthroid | $55 | $6,06452 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
Other endocrinology, diabetes & metabolism in Miami
- Jay SkylerMiami$2.2M
- Eugenio Angueira-SerranoMiami$603K
- Rodolfo GalindoMiami$229K
- Camillo RicordiMiami$128K
- Arelis MaderaPort Charlotte$1.7M
- Damon TantonOrlando$1.2M
- Gaston PonteMelbourne$906K
- Brian LakeLargo$888K
- David SuttonJacksonville$783K
- Mae Sheikh AliJacksonville$751K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.